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Abstract 
Vulnerability in schizophrenia is an integrative concept, which tries to explain the development of 
schizophrenia as an interaction between different individual susceptibility factors and environmental risk 
factors.  Vulnerability  markers  used  in  genetic  studies  include  biochemical  indicators,  neuroanatomical, 
neurophysiologic,  and  cognitive  abnormalities.  Among  those,  the  most  extensive  studied  markers  were: 
evoked potentials, smooth pursuit eye movements, and attentional deficits. Some of the potential indicators 
presented in this paper satisfy most of the criteria necessary for a vulnerability marker, but none meets all of 
them. Nevertheless, they represent important markers of risk to schizophrenia. 
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Introduction 
 
The studies of schizophrenia etiology are 
focused  mostly  on  vulnerability  models,  an 
integrative concept, which has as main objective 
the explanation of the variability of experimental 
and clinical data. This bio-psycho-social approach 
considers that the development of schizophrenia is 
determined  by  the  complex  interaction  between 
different  factors  and  suggest  explanatory 
hypothesis for both the etiology and the clinical 
variability. The concept of vulnerability describes 
the  complex  interactions  between  individual 
susceptibility  factors  and  environmental  risk 
factors. These interactions are at the origin of high 
risk or of the clinical symptomatology. 
The  clinical  heterogeneity  of 
schizophrenia  and  spectrum  disorders  creates 
important  methodological  difficulties  for  genetic 
studies. One solution for the research of genetic 
vulnerability for schizophrenia is the definition of 
endophenotypes,  based  on  clinical,  cognitive,  or 
biological  parameters  (Gottesman  and  Gould, 
2003).  An  efficient  endophenotype  should  be 
reliable, stable, hereditary, and to identify the risk 
of  an  individual  to  develop  the  disease,  as  by 
example the high level of cholesterol indicates a 
risk for cardiovascular disease.     
Graver  (1987)  proposes  the  following 
criteria in defining a vulnerability marker or a trait 
marker, capable of detecting the biological risk to 
develop a psychosis: the different distribution in 
patients  versus  control  group;  higher  prevalence 
in  family  members  than  in  general  population; 
association  with  spectrum  disorders  in  family 
members; correlation with spectrum disorders in 
children with high risk and presence of the marker 
before  the  manifestation  of    clinical  symptoms; 
reliability  and  stability  in  time.  Some  of  the 
markers meet most of the criteria, but none meets 
all of them. 
The  main  advantage  in  using 
endophenotypes  resides  in  their  correlation  with 
functional and structural abnormalities associated 
with  schizophrenia,  and  thus  the  approach  of 
genetic mechanisms becomes more accurate. The 
importance of endophenotypes and their use in the 
research  of  schizophrenia  has  been  extensively 
discussed in the psychiatric literature (Braft and 
Freedman,  2002;  Braft  et  al.,  2007;  Matei  and 
Davidson, 2007a, b). 
Vulnerability  markers  used  in  genetic 
studies  include  biochemical  indicators, 
neuroanatomical,  neurophysiological  and 
cognitive abnormalities, which proved to have a 
significant  heritability  rate  (Szymanski  et  al., 
1994).  Among  those,  most  studied  are:  ocular 
movements  (Peralta  et  al.,  1992;  Greenwood  et 
al., 2007; Martin et al., 2007), evoked potentials 
(Freedman  et  al.,  1997;  Winterer  et  al.,  2003; 
Yeap et al., 2006; Greenwood et al., 2007; Martin 
et al., 2007) and cognitive evaluations (Cannon et 
al.,  2005;  Greenwood  et  al.,  2007;  Gur  et  al., 
2007).  Others  endophenotypes  are  structural 
cerebral  anomalies  (McDonald  et  al.,  2004; 
Cannon  et  al.,  2005;  Gurling  et  al.,  2006)  and 
alterations of D2 dopaminergic receptors densities 
(Hirvonen  et  al.,  2005).  All  these  markers Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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constitute  specific  traits  in  patients  with 
schizophrenia  and  in  a  significant  proportion  of 
their relatives, and thus they represent markers of 
risk to this illness. 
 
Electrophysiological anomalies 
 
Electrophysiological methods do not offer 
data that may be considered specific in psychiatry. 
Although  in  patients  with  schizophrenia, 
electroencephalographic (EEG) registrations show 
numerous  anomalies  (Morihisa  et  al.,  1983; 
Morrison-Stewart  et  al.,  1991;  Gruzelier  et  al. 
1990; Symond et al., 2005; Ferrarelli et al., 2007; 
Knyazeva et al., 2008), more studies are necessary 
to  confirm  their  value  as  biological  markers. 
However, EEG data correlate with those obtained 
by  other  methods:  evoked  potentials, 
polisomnography (Maixner et al., 1998).  
Evoked  potentials  (EP)  represent  the 
answer  of  nervous  cells  to  sensorial  (visual, 
acoustic, tactile) or cognitive stimuli. In the case 
of  cognitive  stimuli,  during  the  registration,  the 
subjects  execute  certain  tasks  or  tests  correlated 
with  sensorial  stimuli,  and  this  is  why  they  are 
also  called  event  related  potentials  (ERP). 
Evaluation of EP illustrates important anomalies 
in patients with schizophrenia, and though they do 
not  have  a  high  specificity,  they  are  promising 
directions  of  research  (Bruder  et  al.,  1999; 
Doniger et al., 2002; Ford et al., 2004; Butler et 
al., 2005; Haenschel et al., 2007). It is important 
to emphasize that in patients with schizophrenia 
EP are heritable (Young et al., 1996; Hall et al., 
2006).  
One of the most studied is the P50 evoked 
potential,  which  demonstrates  abnormalities  in 
patients  with  schizophrenia  and  spectrum 
disorders  (Clementz  et  al.,  1998;  Cadenhead  et 
al., 2000; Siever and Davis, 2004). 
The cognitive psychophysiology research 
was  focused  on  P300  evoked  potential,  which 
seems  to  be  correlated  with  information 
processing  (Ford  et  al.,  2004).  Schizophrenic 
patients show low amplitude of P300 and increase 
in  response  latency  (St  Clair  et  al.,  1989).  The 
decrease  of  visual  and  auditive  P300  amplitude 
could  be  correlated  with  negative  symptoms 
(Pfefferbaum  et  al.,  1989),  and  increase  of 
auditive P300 amplitude with positive symptoms 
(Shenton  et  al.,  1989).  Observed  anomalies  and 
especially increase of latency reflects problems of 
attention and information processing.      
Another  extended  studied  evoked 
potential  in  patients  with  schizophrenia  and 
spectrum  disorders  is  N400,  correlated  with 
semantic  associations  (Nestor  et  al.,  1997; 
Niznikiewicz et al., 1999).  
It  is  important  to  emphasize  that  the 
observed  abnormalities  are  not  specific. 
Anomalies  of  P300  were  seen  in  patients  with 
other  psychiatric  conditions,  such  as  borderline 
personality  disorder  (Blackwood  et  al.,  1986; 
Kutcher et al., 1987) or dementia (Goodin et al., 
1978). Changes of P50 wave were also found in 
patients  with  bipolar  or  schizoaffective  disorder 
(Martin  et  al.,  2007).  The  results  of  the  studies 
concerning  EP  are  thus  variable  and  more 
research is needed in this area.   
The  amount  of  data  brought  by 
electroencephalography  and  evoked  potentials  is 
impressive.  The  quantitative  analysis  and 
topographical  EEG  (Gruzelier  et  al.,  1990)  are 
advanced  methods,  assisted  by  computer,  which 
makes the interpretation of data much easier.   
Karson  et  al.  (1988)  apply  quantitative 
EEG  (QEEG)  in  untreated  patients  with 
schizophrenia and describe a slow alpha rhythm 
associated  with  enlargement  of  lateral  cerebral 
ventricles. QEEG associated with cognitive tests 
enables the analysis of answers to different tests 
and tasks, at cerebral level. These methods have 
limited use and they do not have a clear clinical 
specificity. One of the applications of quantitative 
electrophysiology is the evaluation of effects for 
different  drugs.  The  studies  are  based  on  the 
hypothesis that the substance has a certain impact 
on  behavior  and  therefore  will  determine  a 
specific electrophysiological activity, measurable 
by  EEG.  The  research  in  this  domain 
demonstrates  that  the  main  classes  of 
psychoactive  substances  determine  characteristic 
changes in the spectrum of EEG frequencies, even 
when administrated in acute situations.  
 
Smooth pursuit eye movements 
 
Smooth Pursuit Eye Movements (SPEM) 
were  extensively  investigated  because  they  are 
under genetic control and constitute a biological 
marker  that  could  define  a  vulnerability  to 
schizophrenia  and  spectrum  disorders  (Lee  and 
Williams, 2000). The studies are focused also on 
the  relationship  between  SPEM  and  other 
dysfunctions  of  eye  movements  (saccades) 
observed  in  patients  with  schizophrenia 
(Haraldsson et al., 2008). The physiopathology of 
SPEM  seems  to  be  associated  with  complex 
anomalies, especially in frontal area, but also in 
temporal and cingular areas, but more studies are 
needed in this direction (Lee and Williams, 2000; Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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Tregellas et al., 2004; Hong et al., 2005; Nagel et 
al., 2007).      
SPEM  dysfunctions  were  described  in 
subjects with schizophrenia by numerous authors 
(Moser et al., 1990; Abel et al., 1991; Friedman et 
al., 1991, 1992; Hommer et al., 1991). They are 
found  in  about  50-80%  of  patients  with 
schizophrenia  versus  10%  of  control  subjects 
(Clementz  and  Sweeney,  1990).  The  degree  of 
dysfunction  seems  to  be  significantly  greater  in 
patients  with  schizophrenia  than  in  control 
subjects (Holzman et al., 1984; Holzman, 1987). 
The abnormalities are present in patients in both 
acute and remission phases, as well as in chronic 
patients  (Cegalis  and  Sweeney,  1979;  Iacono  et 
al., 1981; Bartfai et al., 1985; Rea et al., 1989), 
without  specificity  for  a  certain  subgroup  of 
schizophrenias  (Shagass  et  al.,  1974). 
Nevertheless, some authors identify an association 
between  disorganization  syndrome  and  SPEM 
anomalies (Lee et al., 2001).    
Ross  (2003)  emphasizes  that  SPEM 
dysfunctions may be identified even in childhood, 
in subjects with vulnerability to schizophrenia, in 
concordance with the neurodevelopment theory.  
In  order  to  avoid  the  influence  of 
antipsychotic  treatment,  most  authors  compared 
untreated patients (on short periods) with treated 
patients,  without  being  able  to  find  differences 
between  the  two  groups  (Holzman  et  al.,  1974; 
Siever  et  al.,  1986;  Litman  et  al.,  1989). 
Introducing  the  treatment  in  untreated  patients 
does not have a significant impact on results (Levy 
et al., 1983; Kufferle et al., 1990). Campion et al. 
(1992)  study  a  group  of  never  treated  patients 
with schizophrenia and demonstrate that observed 
dysfunctions do not differ in a significant manner, 
from those in chronic patients under treatment. 
Changes  in  SPEM  are  not  specific  to 
schizophrenia (Kathmann et al., 2003). They are 
also found in individuals with spectrum disorders 
(Siever  et  al.,  1990),  and  bipolar  disorder 
(Shagass et al., 1974, Lipton et al., 1980; Iacono 
et al., 1982), but in this last group, the treatment 
with lithium seems to be responsible for changes 
in  SPEM  (Levy  et  al.,  1985;  Holzman  et  al., 
1991).    
Overall, the studies indicate the presence 
of  a  significant  familial  aggregation  for  SPEM 
dysfunctions  and  thus  of  genetic  implication 
(Kathmann et al., 2003; Hong et al., 2006). SPEM 
abnormalities  were  identified  in  30-50%  of 
relatives  of  patients  with  schizophrenia  that 
present  these  anomalies  (Holzman  et  al.,  1974, 
1984; Mather, 1985), in comparison with only a 
small percentage of relatives of patients with other 
disorders.  Some  of  these  studies  evaluate  the 
clinical  status  of  relatives.  The  patients  with 
schizophrenia  and  their  relatives  with  spectrum 
disorders present significant changes in SPEM in 
comparison  with  healthy  relatives  or  control 
group  (Clementz  et  al.,  1990;  Clementz  and 
Sweeney,  1990).  Blackwood  et  al.  (1991) 
demonstrated  the  presence  of  SPEM  anomalies 
for an important percentage of relatives (without 
clinical  manifestations)  of  patients  with 
schizophrenia.  
As for the study of twins discordant for 
schizophrenia, Holzman et al. (1977) found a high 
concordance,  of  80%,  for  these  anomalies  in 
monozygots  and  a  concordance  of  39%  for 
dizygots.  Data  illustrate  the  important  role  of 
genetic factors (Matthysse et al., 1986; Holzman 
et al., 1988; Grove et al., 1992).  
In the studies of relatives of patients with 
schizophrenia, SPEM anomalies contribute to the 
description of an enlarged clinical spectrum that 
includes  subjects  without  symptoms.  In  other 
words, these changes could constitute a  possible 
manifestation  of  a  genetically  determined  latent 
trait, the  symptoms  of  schizophrenia  being  only 
one  of  the  possible  phenotypical  expressions  of 
this trait. The marker is useful in genetic linkage 
studies. 
In conclusion, SPEM abnormalities are a 
biological trait marker, but not a test that could 
confirm  the  diagnosis  of  schizophrenia 
(Szymansky et al., 1994). 
 
Changes in the electrodermal activity 
 
The electrodermal activity is studied for a 
long  time,  and  the  results  show  that  40-50%  of 
patients with schizophrenia present abnormalities, 
versus 5-10% of control group subjects (Holzman, 
1987). The change of electrodermal answer is not 
specific  to  schizophrenia  and  so  it  is  found  in 
other groups of patients as well, especially those 
with  affective  disorders.  Variable  results  were 
obtained when trying to correlate the changes in 
electrodermal  activity  with  the  symptomatology 
(Straube,  1979;  Bernstein  et  al.,  1981;  Öhman, 
1981; Alm et al., 1984; Dawson and Nuechterlein, 
1984; Green et al., 1989; Williams et al., 2003). 
One  of  the  research  areas  is  the  lateralization 
phenomenon, because a left-right asymmetry was 
found  in  the  electrodermal  activity  (Bob  et  al., 
2007a, b). 
The  electrodermal  answer  constitutes  a 
biological marker whose potential value justifies 
more in deep research (Dawson et al., 1992), the 
results  up  to  date  showing  that  electrodermal 
anomalies  are  frequently  associated  with  a  poor Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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outcome  regarding  both  the  symptoms  and  the 
social insertion (Dawson and Schell, 2002; Schell 
et al., 2005). 
 
Cognitive impairement 
 
Attentional  deficits  are  among  the  most 
promising  vulnerability  markers.  Patients  with 
schizophrenia  have  low  performances  in 
numerous  neurocognitive  tests,  which  evaluate 
different  aspects  of  attentional  processes.  Only 
some  of  these  aspects  satisfy  sufficient  criteria 
necessary for a vulnerability marker.    
The  most  accepted  test  for  attentional 
deficits  is  the  Continuous  Performance  Test 
(CPT;  Rosvold  et  al.,  1956),  which  presents 
alterations independent of the stage of the illness 
(Orzack and Kornetsky, 1971; Nuechterlein et al., 
1992;  Cornblatt  and  Keilp,  1994).  Thus, 
attentional deficits evaluated with CPT, especially 
the problems related to the focusing of attention, 
are  considered  a  good  neurophysiological 
indicator for the risk of developing schizophrenia. 
Between  40  and  50%  of  patients  with 
schizophrenia,  show  low  performances  in  CPT 
(Erlenmeyer-Kimling  and  Cornblatt,  1987). 
Treatment  may  improve  results  of  patients  with 
schizophrenia, but these remain inferior to those 
obtain by the control group (Harvey et al., 1990; 
Serper  et  al.,  1990;  Earle-Boyer  et  al.,  1991). 
Nevertheless, there are studies that do not confirm 
the up-mentioned results (Finkelstein et al., 1997; 
Addington and Addington, 1997). 
Cornblatt  and  Keilp  (1994)  emphasize 
that  attentional  deficits  are  not  only  present 
independent of the patients’ clinical status but are 
also  detectable  before  the  onset  of  illness  and 
seem to be hereditary, observation confirmed by 
other  studies.  Decreased  performances  at  CPT 
were also registered in subjects with high risk for 
schizophrenia  (Nuechterlein,  1983;  Nuechterlein 
et al., 1986; Erlenmeyer-Kimling and Cornblatt, 
1987;  Goldberg  et  al.,  1990;  Lezenweger  et  al., 
1991;  Maier  et  al.,  1992;  Franke  et  al.,  1994; 
Chen et al., 1998), and these findings support the 
genetic implications of attentional deficits. 
In conclusion, although in schizophrenic 
patients  different  other  attention  tests  were 
applied,  CPT  remains  the  most  useful  and 
recognized. 
Among  the  cognitive  impairments  of 
patients  with  schizophrenia,  considered  good 
candidates  as  vulnerability  markers,  are  the  low 
performances  in  tests  sensitive  at  the  change  of 
frontal  functions,  especially  Wisconsin  Card 
Sorting  Test  (WCST;  Berg,  1948).  The 
impairments  at  this  test  (Franke  et  al.,  1993, 
Lezenweger  and  Korfine,  1994)  support  the 
hypothesis of the role played by the frontal area in 
the  vulnerability  to  schizophrenia.  Functional 
imagistic  procedures,  as  well  as 
electroencephalographic ones, applied during the 
execution  of  cognitive  tests  support  this 
correlation (Buchsbaum et al., 1990; Hoffman et 
al., 1991; Mann et al., 1997), the results strongly 
suggesting  the  role  of  prefrontal  area  in  the 
vulnerability for schizophrenia.    
Research  of  cognitive  and  behavioral 
markers  include  evaluations  of  neurobehavioral 
performances  (motor,  visual-motor,  attentional, 
cognitive)  as  well  as  the  evaluation  of  social 
functioning,  organizing  capacity,  intelligence, 
individual autonomy in subjects at risk but also in 
apparently healthy young individuals (Davidson et 
al.,  1999;  Hans  et  al.,  1999;  Gur  et  al.,  2007). 
These  indicators  are  usefully  in  identifying  the 
risk to develop schizophrenia.    
 
Neuro-psycho-endocrinological anomalies 
 
The  main  hypotheses  of  the  role  of 
hormonal  changes  in  schizophrenia  (Lembreghts 
and Ansseau, 1993; Liberman and Koreen, 1993) 
are  illustrated  by  the  studies  of  the  growth 
hormone  and  the  hypothalamic-pituitary-adrenal 
system,  and  especially  the  interactions  of  these 
with  the  neurotransmitters  (Bennett,  2008; 
Pruessner et al., 2008; Walker et al., 2008). The 
relation  between  cortisol  and  glutamate,  and 
cortisol and dopamine were more studied, but the 
results are inconclusive. 
More  important  seems  to  be  the 
estrogenic  hypothesis,  which  is  correlated  with 
later onset of illness, better premorbid functioning 
and  better  outcome  of  schizophrenia  in  women 
than  in  men.  Estrogen  impact  upon  central 
nervous system is studied through the interactions 
with: dopamine (Häfner et al., 1991; Bossé and 
Di Paolo, 1996), serotonin (Bossé and Di Paolo, 
1996; Sumner and Fink, 1995; Fink et al., 1996; 
McQueen  et  al.,  1997),  gamma-amino-butyric 
acid (Bossé and Di Paolo, 1996), and glutamate 
(Gazzaley et al., 1996; Diano et al., 1997). This is 
one of the explanatory models of the variability of 
schizophrenia in women versus men and it might 
have  some  therapeutic  implications  (Kulkarni  et 
al., 2001, 2008). 
Immune markers 
 
The hypothesis of an immune dysfunction 
was approached from different perspectives. One Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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of  the  most  interesting  concepts  refers  to  the 
implication  of  autoimmune  mechanisms 
(Goldsmith and Rogers, 2008), but the results do 
not allow significant conclusions. 
The most frequent modifications observed 
include  interleukins,  lymphocytes,  antinuclear 
antibodies, which suggest that in the etiology of 
schizophrenia  immune  abnormalities  could  play 
an  important  role  (Müller  et  al.,  1999,  2000; 
Printz et al., 1999; Tanaka et al., 2000). 
The hypothesis of a viral infection during  
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